TP-252 for Treatment of Ulcerative Colitis (UC)
A pre-clinical asset with clinical proof of concept on the active agent.
TP-252 is a novel derivative of eicosapentaenoic acid free fatty acid (EPA-FFA), which has been shown in an independent Phase 2 RCT to have efficacy in reducing relapse in ulcerative colitis (UC) patients and is known to play a critical role in regulating the body’s inflammatory-immune response. TP-252 is being developed as oral therapy for the maintenance of remission in UC patients with a history of mild to moderate disease. TP-252, as adjunct therapy to first-line 5-ASA therapy, would provide a clinically-meaningful benefit to UC patients by controlling the underlying inflammation and reducing the frequency and severity of disease relapses, thus reducing the need for more aggressive therapeutic agents and the risk of potentially serious adverse events. Thetis expects to begin clinic studies in 2018.